CTOs on the Move


 
Indiva is a Canadian licensed producer of premium cannabis and cannabis products, and a provider of extraction, manufacturing and refinement services.
  • Number of Employees: 25-100
  • Annual Revenue: $0-1 Million
  • www.indiva.com
  • 1050 Hargrieve Drive Unit 10
    London, ON CAN N6E 1P5
  • Phone: N/A

Executives

Name Title Contact Details

Funding

Indiva raised $14M on 10/16/2019
Indiva raised $11M on 02/16/2021

Similar Companies

REDCON1

REDCON1 is a company that creates premium nutritional supplements for athletes of all levels, with the objective of bringing them to the highest state of readiness.

Aurora Cannabis

Aurora Cannabis Inc. is a world-renowned integrated cannabis company with an industry-leading reputation for continuously elevating and setting the global cannabis industry standard. Through our wholly owned subsidiaries, strategic investments, and global partnerships, Aurora provides a wide range of premium quality cannabis and hemp products and services, develops innovative technologies, promotes cannabis consumer health and wellness, and delivers an exceptional customer experience across all its brands. Aurora`s operations span multiple continents and focuses on both the medical and recreational cannabis production and sales, patient education and clinic counselling services, home hydroponic cultivation, extraction technologies and delivery systems, and hemp-based food health products. We operate around the globe pursuing new and emerging cannabis markets where possible through our owned network of import, export and wholesale distributors, and our e-commerce and mobile applications.

Huber Kältemaschinen

Temperature Control Solutions for Laboratory and Production from -125 °C to +425 °C

Intertek Pharmaceutical Services

Intertek Pharmaceutical Services is a Whitehouse, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Diamedica

DiaMedica Inc., a development stage biopharmaceutical company, is engaged in the discovery and development of drugs for the treatment of diabetes and related diseases. The company`s lead clinical stage compound is DM199, a recombinant human protein known as rhKLK1, which is under phase I/II clinical trials for the treatment of Type 1 and Type 2 diabetes and associated complications. It is also developing DM204, a monoclonal antibody that is in preclinical development for the treatment of Type 2 diabetes; and DMDx, a chronic kidney disease assay to detect levels of the tissue kallikrein-1 protein in urine and to predict the rate of kidney disease progression. The company was formerly known as Diabex Inc. and changed its name to DiaMedica Inc. in February 2001. DiaMedica Inc. was incorporated in 2000 and is headquartered in Minneapolis, Minnesota.